Image Source: Zacks Investment ... shares of Novo Nordisk’s archrival in the obesity market space, Eli Lilly LLY, gained as its marketed drug, Zepbound (tirzepatide), continues to maintain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback